Triptorelin
DB06825
Approved Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
1
Targets
0
Resistance Mutations
2
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Triptorelin is a synthetic agonist analog of gonadotropin releasing hormone (GnRH). Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone.
Details
DrugBank ID
DB06825 ↗
Approval Date
2000-06-15
Molecular Weight
1311.473 g/mol
Drug Class
Other
ATC Codes
L02AE04
Synonyms
(D-Trp6)-GnRH, triptorelina, triptoreline
PubChem
CID: 25074470 ↗
ChEMBL
CHEMBL1201334 ↗
SMILES
CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
ADMET Profile
Computing properties…
Drug References (DrugBank)